# 2025年12月11日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 利用拉普拉斯方差对甲状腺液基细胞学全切片成像的聚焦质量进行定量评估

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41369778)
**期刊：** Endocrine pathology
**PMID：** 41369778
**DOI：** 10.1007/s12022-025-09893-w

### 第一部分 原文与翻译

**英文原标题：** Quantitative Assessment of Focus Quality in Whole-Slide Imaging of Thyroid Liquid-Based Cytology Using Laplacian Variance.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要可用。

### 第二部分 AI 大师评价

本研究旨在探讨采用拉普拉斯方差方法对甲状腺液基细胞学全切片图像的聚焦质量进行定量评估。该方法通过客观的计算机视觉算法评估成像清晰度，为病理全数字化影像的质量控制提供了新思路。研究的创新在于引入量化指标以替代主观聚焦评估，从而提高检测可靠性。由于目前尚无摘要，具体实验设计与验证细节仍需进一步查阅原文，以确认方法的鲁棒性与临床可扩展性。

---

## 2. HER2CLIMB-05：一项评价图卡替尼联合曲妥珠单抗与帕妥珠单抗对比安慰剂用于HER2阳性转移性乳腺癌一线维持治疗的Ⅲ期研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41369677)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41369677
**DOI：** 10.1200/JCO-25-02600

### 第一部分 原文与翻译

**英文原标题：** HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast Cancer.

> **英文摘要：**
> PURPOSE: The HER2CLIMB-05 study (ClinicalTrials.gov identifier: NCT05132582) is investigating the efficacy and safety of adding tucatinib to trastuzumab and pertuzumab as first-line (1L) maintenance therapy in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC).
> 
> PATIENTS AND METHODS: Patients with centrally confirmed HER2+ MBC without evidence of progression post-induction therapy and no or asymptomatic brain metastases (BM) were enrolled. Patients were randomly assigned 1:1 to tucatinib (300 mg) or placebo BID combined with trastuzumab/pertuzumab. Primary endpoint is investigator-assessed progression-free survival (PFS); secondary endpoints include overall survival (OS), PFS per blinded independent central review, CNS-PFS, and safety.
> 
> RESULTS: Between March 2022 and July 2024, 654 patients were randomly assigned to tucatinib (n = 326) and placebo (n = 328) arms. All patients were female (median age: 54 years), 69.3% had  MBC, 52.6% were hormone receptor-positive, and 12.4% had presence/history of baseline BM. In this primary analysis, PFS was statistically significantly improved with addition of tucatinib versus placebo (hazard ratio = 0.641 [95% CI: 0.514, 0.799];  < 0.0001; median PFS: 24.9 vs 16.3 months); a PFS benefit was seen regardless of presence/absence of BM or hormone receptor status. OS data remains immature. The most common treatment-emergent adverse events (TEAEs) in the tucatinib arm were diarrhea (72.7%), nausea (33.1%), and elevated liver enzymes (alanine aminotransferase: 28.2%; aspartate aminotransferase: 25.8%), of which 6.1%, 0.9%, 13.5%, and 7.1%, respectively, were grade ≥3. In the tucatinib arm, 13.5% discontinued tucatinib due to TEAEs.
> 
> CONCLUSIONS: Tucatinib addition to trastuzumab and pertuzumab demonstrated improvement in PFS with no new safety signals identified and may be an option for 1L maintenance therapy in patients with HER2+ MBC.

> **中文摘要：**
> 研究目的：HER2CLIMB-05研究（ClinicalTrials.gov注册号：NCT05132582）旨在探讨在HER2阳性转移性乳腺癌（HER2+ MBC）患者中，将图卡替尼联合曲妥珠单抗和帕妥珠单抗用于一线（1L）维持治疗的疗效与安全性。
> 
> 患者与方法：纳入经中心确认HER2阳性、经诱导治疗后未出现疾病进展、且无脑转移或仅有无症状脑转移（BM）的MBC患者。患者以1:1比例随机分配接受图卡替尼（300 mg）或安慰剂，每日两次，与曲妥珠单抗/帕妥珠单抗联合给药。主要终点为研究者评估的无进展生存期（PFS）；次要终点包括总生存期（OS）、盲态独立中心评审的PFS、中枢神经系统PFS（CNS-PFS）及安全性。
> 
> 研究结果：在2022年3月至2024年7月期间，共654例患者被随机分配至图卡替尼组（n=326）和安慰剂组（n=328）。所有患者均为女性，中位年龄54岁；69.3%为转移性乳腺癌，52.6%为激素受体阳性，12.4%有基线脑转移或既往脑转移病史。在主要分析中，相较安慰剂组，图卡替尼组PFS显著改善（风险比=0.641 [95% CI: 0.514, 0.799]；p<0.0001；中位PFS：24.9个月 vs 16.3个月）；无论是否存在脑转移或激素受体状态如何，均观察到PFS获益。OS数据尚不成熟。图卡替尼组最常见的治疗相关不良事件（TEAEs）为腹泻（72.7%）、恶心（33.1%）及肝酶升高（丙氨酸转氨酶28.2%，天冬氨酸转氨酶25.8%），其中分别有6.1%、0.9%、13.5%及7.1%为≥3级。图卡替尼组中有13.5%的患者因TEAEs停用图卡替尼。
> 
> 研究结论：在曲妥珠单抗和帕妥珠单抗方案中加入图卡替尼可显著改善PFS，且未观察到新的安全性信号，或可作为HER2阳性转移性乳腺癌患者的一线维持治疗选择。

### 第二部分 AI 大师评价

该研究为一项设计严谨的Ⅲ期随机对照试验，评估了图卡替尼联合曲妥珠单抗与帕妥珠单抗作为HER2阳性转移性乳腺癌一线维持治疗的价值。研究结果显示，该方案显著延长无进展生存期，且在有无脑转移及激素受体状态不同的亚组中均具一致性。安全性方面未出现新的不良信号，但肝酶升高与腹泻仍需关注。总体而言，该研究为优化HER2阳性转移性乳腺癌一线维持治疗提供了新的循证依据，但需进一步随访总生存数据以确认长期获益。

---

## 3. 靶向肿瘤治疗药物相关心血管不良反应的诊断与管理：布鲁顿酪氨酸激酶抑制剂、免疫检查点抑制剂及血管内皮生长因子抑制剂——2025年美国心脏病学会简明临床指南：美国心脏病学会解决方案集监督委员会报告。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41369617)
**期刊：** Journal of the American College of Cardiology
**PMID：** 41369617
**DOI：** 10.1016/j.jacc.2025.10.018

### 第一部分 原文与翻译

**英文原标题：** Diagnosis and Management of Cardiovascular Adverse Effects of Targeted Oncology Therapies: Bruton's Tyrosine Kinase, Immune Checkpoint, and Vascular Endothelial Growth Factor Inhibitors: 2025 ACC Concise Clinical Guidance: A Report of the American College of Cardiology Solution Set Oversight Committee.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本指南全面总结了靶向肿瘤治疗中几类关键药物所致心血管不良反应的识别与处理策略，体现出肿瘤学与心脏病学交叉领域的最新共识。报告由美国心脏病学会专家委员会发布，旨在提供简明实用的临床指导。尽管缺乏原始研究数据，但它在整合既有证据与临床经验方面具有高度权威性，为临床实践提供了重要参考。

---

## 4. CXCL9 作为一种新型预后标志物用于识别高危成人噬血细胞性淋巴组织细胞增生症患者

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41369611)
**期刊：** Blood
**PMID：** 41369611
**DOI：** 10.1182/blood.2025030976

### 第一部分 原文与翻译

**英文原标题：** CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis.

> **英文摘要：**
> Hemophagocytic lymphohistiocytosis (HLH) is an interferon-γ-driven hyperinflammatory syndrome with high morbidity and mortality. Identifying reliable prognostic biomarkers is challenging due to various predisposing conditions and triggers. CXCL9 is a clinically-validated biomarker and surrogate marker of interferon-γ-mediated inflammation. We aimed to identify the role of CXCL9 in predicting severe disease and death in adults with HLH using a multicenter retrospective cohort of consecutively hospitalized patients undergoing a clinical evaluation for HLH that included CXCL9 testing. Patients were classified as HLH if they met HLH-2004 and/or HScore criteria. Conditional-inference decision trees and Cox regression models were used to identify which clinical variables associated with acute mortality in HLH patients. Overall, 171-patients were reviewed and 126-patients met HLH criteria. Median age was 55-years (IQR: 40-66) with 77 (62%) male and 64 (51%) White. CXCL9 was markedly elevated in HLH patients. Unbiased decision tree modeling, incorporating all clinical laboratory values, identified only CXCL9 >16,100 pg/mL as the optimal predictor of inpatient mortality (p=0.009). Cox regression models demonstrated CXCL9 >16,100 pg/mL was significantly associated with 90-day mortality (hazard ratio, 3.0; 95%CI 1.6-5.6, p=0.003) when controlling for age, sex, race, malignancy, and HLH-targeted therapy. This shorter time-to-death in the elevated CXCL9 subgroup remained significant even after subdividing patients into malignancy (n=53) and non-malignancy-HLH (n=73) (log-rank, p<0.05). Continuous increases in CXCL9 within the cohort strongly associated with greater mortality. CXCL9 is a novel clinical marker that identifies high-risk HLH independent of underlying disease and could be used to select patients for early and aggressive targeted-immunomodulatory therapy.

> **中文摘要：**
> 噬血细胞性淋巴组织细胞增生症（HLH）是一种由干扰素-γ驱动的高炎症综合征，具有高发病率和高死亡率。由于存在多种易感条件和诱因，确定可靠的预后生物标志物具有挑战性。CXCL9是一种经过临床验证的生物标志物，同时也是干扰素-γ介导炎症的替代指标。本研究旨在利用多中心回顾性队列研究，评估在接受HLH临床评估（包括CXCL9检测）的连续住院成人患者中，CXCL9在预测重症及死亡风险中的作用。若患者符合HLH-2004和/或HScore标准，即被归类为HLH。研究采用条件推断决策树和Cox回归模型，识别与HLH患者急性死亡相关的临床变量。共回顾171例患者，其中126例符合HLH标准。患者中位年龄为55岁（四分位范围：40–66），其中77例（62%）为男性，64例（51%）为白人。HLH患者的CXCL9水平显著升高。非偏倚决策树建模综合所有实验室指标后，仅发现CXCL9 >16,100 pg/mL 是院内死亡率的最佳预测因子（p=0.009）。Cox回归模型显示，在校正年龄、性别、种族、恶性肿瘤及HLH针对性治疗后，CXCL9 >16,100 pg/mL 仍与90天死亡率显著相关（风险比3.0；95%置信区间1.6–5.6，p=0.003）。即使将患者分为合并恶性肿瘤（n=53）和非恶性HLH（n=73）亚群，CXCL9升高组的生存期显著更短（log-rank，p<0.05）。在整个队列中，CXCL9的持续升高与更高死亡率密切相关。CXCL9是一种新型临床标志物，可独立于基础疾病识别高危HLH患者，并可用于选择需早期强化靶向免疫调节治疗的对象。

### 第二部分 AI 大师评价

本研究聚焦CXCL9在成人噬血细胞性淋巴组织细胞增生症中作为预后标志物的价值，采用多中心回顾性队列分析和统计建模验证其预测死亡风险的能力。结果显示，CXCL9浓度超过16,100 pg/mL可独立预测院内及90天内死亡风险。研究创新地提出CXCL9可作为独立于基础病因的高危标志，用于指导患者早期强化免疫干预。然而，研究受限于回顾性设计及样本集中于住院患者，需进一步前瞻性验证。

---

## 5. 小胶质细胞对播散性肿瘤细胞呈现异质性的初始反应

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41369553)
**期刊：** Cancer research
**PMID：** 41369553
**DOI：** 10.1158/0008-5472.CAN-25-3425

### 第一部分 原文与翻译

**英文原标题：** Microglia Display Heterogeneous Initial Responses to Disseminated Tumor Cells.

> **英文摘要：**
> Brain metastases are frequent and often lethal complications of advanced cancers. Microglia, resident immune cells of the brain, are known to exert both anti-tumor and pro-tumor functions in late-stage metastases; however, their response during the initial outgrowth of metastatic lesions is not well characterized. Understanding how heterogeneous microglial subgroups are regulated in the developing tumor microenvironment could pave the way for therapeutic strategies to eliminate metastatic tumors at an early stage. In this study, we used a combination of in vivo fate map imaging, single-cell RNA sequencing, and a holographic photoconversion-based technique (Opto-omics) to track tumor fate and early microglial responses over time in the same animals during colonization of disseminated tumor cells. The microglial population was transcriptionally and morphologically heterogeneous, comprising both pro- and anti-tumor subsets. Genetic and pharmacological perturbations revealed that microglial phenotypes could be shifted by inhibiting TGF-β signaling or by deleting the tumor cell surface antigens CD24a and CD47. These findings reveal targetable plasticity in early-stage microglial responses to brain metastasis and suggest that harnessing pro-phagocytic microglial states may offer a therapeutic window before systemic immunosuppression becomes dominant.

> **中文摘要：**
> 脑转移是晚期癌症中常见且常致命的并发症。小胶质细胞是脑内的常驻免疫细胞，已知在晚期转移中既可发挥抗肿瘤作用，也可促进肿瘤生长；然而，它们在转移灶初期生长阶段的反应尚不清楚。理解肿瘤微环境发育过程中异质性小胶质细胞亚群的调控机制，可能为早期清除转移性肿瘤提供治疗策略。在本研究中，我们结合了体内命运图谱成像、单细胞RNA测序以及基于全息光转换的技术（Opto-omics），以在同一动物体内随时间追踪播散性肿瘤细胞定植过程中的肿瘤命运及早期小胶质细胞反应。结果显示，小胶质细胞群体在转录和形态水平上均表现出异质性，包含促肿瘤和抗肿瘤两类亚群。遗传和药理学干预实验表明，通过抑制TGF-β信号通路或敲除肿瘤细胞表面抗原CD24a和CD47，可以改变小胶质细胞的表型。这些发现揭示了早期小胶质细胞对脑转移反应的可靶向可塑性，并提示调动促吞噬性小胶质细胞状态可能在系统性免疫抑制占主导之前提供一个治疗窗口。

### 第二部分 AI 大师评价

本研究旨在解析脑转移早期阶段小胶质细胞的动态反应特征，结合体内成像、单细胞组学及光学标记技术开展纵向追踪实验。结果揭示小胶质细胞具有显著的功能和转录异质性，可在促肿瘤与抗肿瘤状态之间转变。通过干预TGF-β信号或去除肿瘤表面抗原，研究者证明了其可塑性及潜在治疗靶点。该研究创新性地描绘了转移早期免疫微环境的动态调控图谱，为早期干预脑转移提供了新视角，但仍需进一步在临床模型中验证其可转化性。

---

## 6. DNA甲基化谱预测SF1谱系非功能性垂体神经内分泌瘤术后复发生长。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41369112)
**期刊：** Neuro-oncology
**PMID：** 41369112
**DOI：** 10.1093/neuonc/noaf269

### 第一部分 原文与翻译

**英文原标题：** DNA Methylation Profiling Predicts Post-Surgical Regrowth in SF1-lineage Nonfunctioning Pituitary Neuroendocrine Tumors.

> **英文摘要：**
> BACKGROUND: Nonfunctioning pituitary neuroendocrine tumors (NFPitNETs) account for ∼30-35% of PitNETs; ∼75% arise from the SF1 lineage. Recurrence remains common despite resection (∼30% in 10 years), and routine histopathology/IHC has limited value in predicting recurrence risk. This study evaluated whether DNA methylation profiling improves recurrence risk stratification.
> 
> MATERIAL AND METHODS: Genome-wide tissue methylation (Illumina EPIC v1, 850K) was analyzed in 117 retrospective NFPitNETs with clinical and imaging follow-up. Unsupervised consensus clustering defined methylation-based subgroups, followed by supervised differential methylation analysis to identify cluster-specific differentially methylated probes (DMPs). A classifier was trained using these signatures, with predicted subgroup memberships correlated with regrowth and progression-free survival (PFS). To ensure reliable estimations, longitudinal mixed-effects models were restricted to the interval of model stability (∼9 years), reflecting cohort follow-up. External validation was performed in three independent cohorts.
> 
> RESULTS: Five clusters (k1-k5) emerged: four SF1 positive-predominant (k1, k2, k3, k5) and one TPIT/PIT1-enriched NFPitNETs (k4). Among the 562 differentially methylated probes, many mapped to genes regulating cell-cycle and immune pathways. Compared with k1-k2, k3, k4, and k5 possessed significantly higher recurrence risk. Within SF1-lineage tumors, k3 exhibited postoperative tumor-volume expansion beginning at ∼6 years. The methylation-based classifier achieved ∼97% accuracy in assigning clusters and maintained prognostic separation across independent cohorts.
> 
> CONCLUSIONS: DNA methylation profiling identifies biologically and clinically distinct NFPitNET subgroups, particularly within the SF1 lineage, and may enhance prediction of recurrence risk. Prospective validation and demonstration of clinical utility are warranted to support integration into precision management workflows.

> **中文摘要：**
> 背景：非功能性垂体神经内分泌瘤（NFPitNETs）约占所有垂体神经内分泌瘤的30–35%，其中约75%源自SF1谱系。尽管进行了手术切除，但复发仍然常见（10年内约30%），而常规的组织病理学/免疫组化（IHC）在预测复发风险方面作用有限。本研究旨在评估DNA甲基化谱分析是否能改进复发风险分层。
> 
> 材料和方法：在117例具有临床及影像随访资料的回顾性NFPitNET病例中，使用全基因组甲基化芯片（Illumina EPIC v1，850K）进行分析。通过无监督一致性聚类定义甲基化基础的亚群，随后进行有监督的差异甲基化分析以鉴定各亚群特异的差异甲基化探针（DMPs）。利用这些特征训练分类器，并将预测的亚群归属与肿瘤再生长及无进展生存期（PFS）相关联。为确保估计可靠性，纵向混合效应模型限定在模型稳定的时间区间（约9年），以反映队列的随访期。研究还在三个独立队列中进行了外部验证。
> 
> 结果：共识聚类识别出五个亚群（k1–k5）：其中四个以SF1阳性为主（k1、k2、k3、k5），一个富集有TPIT/PIT1相关的NFPitNETs（k4）。在562个差异甲基化探针中，许多定位于调控细胞周期及免疫通路的基因。相比k1–k2，k3、k4和k5的复发风险显著升高。在SF1谱系肿瘤中，k3亚群在术后约6年开始出现肿瘤体积扩增。基于甲基化的分类模型在聚类归属中的准确率约为97%，并在独立队列中保持了良好的预后区分能力。
> 
> 结论：DNA甲基化谱能够识别出生物学和临床上不同的NFPitNET亚型，尤其是在SF1谱系中，可增强复发风险预测。仍需前瞻性验证及临床实用性评估，以支持其纳入精准管理流程。

### 第二部分 AI 大师评价

该研究旨在通过DNA甲基化谱改进非功能性垂体神经内分泌瘤复发风险的预测。研究基于117例病例的全基因组甲基化数据进行无监督聚类与差异甲基化分析，并建立分类器进行内部与外部验证。结果发现SF1谱系内存在生物学与临床特征显著不同的亚群，部分亚群术后复发风险更高。本研究创新性地将甲基化组学应用于垂体瘤风险分层，为精准管理提供了新思路，但其临床可行性仍需前瞻性研究进一步验证。

---

## 7. 机器人辅助与开放及腹腔镜胰十二指肠切除术对比：日本全国匹配研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41366840)
**期刊：** Annals of surgery
**PMID：** 41366840
**DOI：** 10.1097/SLA.0000000000006996

### 第一部分 原文与翻译

**英文原标题：** Robotic Versus Open and Laparoscopic Pancreaticoduodenectomy: A Nationwide Matched Study in Japan.

> **英文摘要：**
> OBJECTIVE: To evaluate real-world clinical outcomes of robotic pancreaticoduodenectomy (PD) versus open and laparoscopic PD in a nationwide cohort.
> 
> SUMMARY BACKGROUND DATA: While robotic PD has gained popularity as a minimally invasive approach to pancreatic surgery, its clinical effectiveness remains uncertain owing to the limited generalizability of existing evidence.
> 
> METHODS: Data from the Japanese National Clinical Database, which captures over 95% of surgical procedures conducted nationwide, were analyzed. Patients who underwent PD between January 2019 and December 2023 were included. Propensity score matching was used to compare robotic PD with open and laparoscopic PD.
> 
> RESULTS: Among 46,166 eligible PD cases, 1,371 were robotic. To ensure consistent surgical proficiency, the analysis included cases performed at institutions conducting ≥20 PDs annually (n=23,613). Following 1:1 matching, 1,248 robotic-open and 1,066 robotic-laparoscopic pairs were identified. Robotic PD was associated with a lower severe complication incidence than that with open (22.2% vs. 25.9%; odds ratio, 0.82; 95% confidence interval, 0.68-0.98; P=0.031) and laparoscopic PD (23.0% vs. 27.6%; odds ratio, 0.78; 95% confidence interval, 0.64-0.95; P=0.015). Robotic PD was also associated with a lower incidence of pancreatic fistula and shorter hospital stay, despite extended operative time. An increased incidence of deep venous thrombosis was observed in the robotic PD group.
> 
> CONCLUSIONS: In this nationwide, Japanese credentialed setting, robotic PD was associated with improved short‑term outcomes compared with those of open and laparoscopic PD. As PD outcomes are influenced by surgeon/institutional experience and case complexity (tumor factors), these aspects should be carefully considered when selecting robotic PD.

> **中文摘要：**
> 目的：评估在日本全国队列中，机器人辅助胰十二指肠切除术（PD）与开放及腹腔镜PD的真实临床结局。
> 
> 背景资料概要：尽管机器人PD作为胰腺外科的微创方法已日益普及，但由于现有证据的推广性有限，其临床有效性仍不确定。
> 
> 方法：分析日本国家临床数据库中收集的数据，该数据库涵盖全国超过95%的外科手术。纳入2019年1月至2023年12月期间接受PD的患者。使用倾向评分匹配比较机器人PD与开放及腹腔镜PD的结局。
> 
> 结果：在46,166例符合条件的PD病例中，1,371例为机器人手术。为确保手术熟练度一致，分析仅包括每年进行≥20例PD的机构（n=23,613）。经1:1匹配后，获得了1,248对机器人-开放组及1,066对机器人-腹腔镜组。与开放组相比，机器人PD严重并发症发生率更低（22.2%对25.9%；比值比0.82；95%置信区间0.68–0.98；P=0.031）；与腹腔镜组相比亦如此（23.0%对27.6%；比值比0.78；95%置信区间0.64–0.95；P=0.015）。尽管手术时间延长，机器人PD与较低的胰瘘发生率及较短的住院时间相关。但机器人组观察到深静脉血栓发生率增加。
> 
> 结论：在日本全国认证的医疗环境中，机器人PD较开放及腹腔镜PD具有更优的短期结局。由于PD的结果受术者／机构经验及病例复杂度（肿瘤因素）影响，选择机器人PD时应慎重权衡这些因素。

### 第二部分 AI 大师评价

该研究利用日本国家临床数据库的大规模数据，系统比较了机器人、开放及腹腔镜三种胰十二指肠切除术方式的短期结局。研究采用倾向评分匹配以控制混杂因素，发现机器人手术可明显降低严重并发症和胰瘘发生率，并缩短住院时间。其创新之处在于以全国真实世界数据支持机器人PD的临床优势。然而，操作时间较长及深静脉血栓风险上升提示仍需优化术中管理，并进一步验证长期结局。

---

## 8. 苯达莫司汀联合利妥昔单抗一线治疗Waldenström巨球蛋白血症患者的晚期毒性与长期疗效研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41366533)
**期刊：** Leukemia
**PMID：** 41366533
**DOI：** 10.1038/s41375-025-02833-x

### 第一部分 原文与翻译

**英文原标题：** Late toxicity and long-term efficacy of first-line bendamustine and rituximab combination in patients with Waldenström macroglobulinemia.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

该研究聚焦于苯达莫司汀联合利妥昔单抗作为Waldenström巨球蛋白血症一线治疗方案的长期安全性与疗效，旨在评估其迟发毒性及持续治疗获益。尽管摘要缺失，但从标题推测，研究可能基于长期随访数据，对治疗的持续缓解率及不良反应进行了系统分析。这类研究对于优化治疗方案、延长患者生存期具有重要的临床意义，也为今后制定更加精准的个体化治疗策略提供了参考。

---

## 9. PRDM1在人类NK细胞分化与活化中的关键调控作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41366532)
**期刊：** Leukemia
**PMID：** 41366532
**DOI：** 10.1038/s41375-025-02815-z

### 第一部分 原文与翻译

**英文原标题：** Key regulatory roles of PRDM1 in human NK-cell differentiation and activation.

> **英文摘要：**
> PRDM1, encoding a transcription factor (TF), regulates plasma cell and CD8 T-cell terminal differentiation and T2 lineage specification, while its role in human NK-cell differentiation and homeostasis is largely unknown. Here, we employed a multi-omics approach to dissect the transcriptional control of PRDM1 on human NK-cells. PRDM1 is important in NK-cell terminal differentiation based on gene expression profiling and its targeting of key regulators in the process. PRDM1-deleted NK-cells displayed a less mature phenotype simulating the CD56 NK-cell population accompanied by upregulation of stem-like gene signatures. PRDM1-bound genes were enriched in T/NK-cell receptor signaling, activation, and NK-cell effector functions. PRDM1 could function as a transcriptional repressor as well as an activator as its activities may be modified by association with different TFs and co-factors. The kinetics of its action also varies among its target genes. As a homeostatic factor, PRDM1 is induced upon IL-2 and feeder cell stimulation, but its ability to restrict NK-cell growth upon feeder stimulation may be counteracted by the AP-1-induced transcriptional network. The loss of PRDM1 activity is frequent in NK-cell malignancies which may lead to decreased homeostatic control, impaired terminal differentiation, enhanced cellular fitness, and the acquisition of more stem-like features, thereby promoting lymphomagenesis.

> **中文摘要：**
> PRDM1编码一种转录因子（TF），调控浆细胞和CD8 T细胞的终末分化及T2谱系特异性，但其在人类NK细胞分化和稳态中的作用尚不清楚。在本研究中，我们采用多组学方法解析PRDM1在人类NK细胞中的转录调控功能。基因表达谱和其靶向关键调控因子的分析显示，PRDM1在NK细胞终末分化中具有重要作用。敲除PRDM1的NK细胞表现出更不成熟的表型，类似于CD56 NK细胞群，并伴随干细胞样基因特征的上调。PRDM1结合的基因富集于T/NK细胞受体信号传导、活化及NK细胞效应功能相关通路。PRDM1既可作为转录抑制因子，也可充当激活因子，其活性可能因与不同转录因子和辅因子相互作用而改变。其作用动力学在不同靶基因间亦存在差异。作为稳态调控因子，PRDM1在IL-2及饲养细胞刺激下被诱导，但其在饲养刺激条件下限制NK细胞生长的能力，可能被AP-1诱导的转录网络所抵消。PRDM1活性的缺失在NK细胞恶性肿瘤中较为常见，可能导致稳态调控下降、终末分化受损、细胞适应性增强及获得更多干细胞样特征，从而促进淋巴瘤发生。

### 第二部分 AI 大师评价

该研究旨在阐明PRDM1在人类NK细胞分化及稳态维持中的调控作用。作者利用多组学整合分析揭示了PRDM1在终末分化阶段的关键功能及其对重要基因调控网络的影响。研究发现PRDM1既可作为转录抑制因子，也可作为激活因子，其功能依赖相互作用的转录因子与辅因子环境。结果为理解NK细胞发育不全和NK细胞相关肿瘤发生的分子机制提供了重要线索，但仍需进一步在体模型中验证其调控网络的动态性。

---

## 10. REL 过度表达及与 2p 臂增益相关的持续 NF-κB 信号在慢性淋巴细胞白血病中诱导 BTK 抑制剂耐药。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41366531)
**期刊：** Leukemia
**PMID：** 41366531
**DOI：** 10.1038/s41375-025-02818-w

### 第一部分 原文与翻译

**英文原标题：** REL overexpression and sustained NF-κB signaling associated with 2p gain induce resistance to BTK inhibitors in Chronic Lymphocytic Leukemia.

> **英文摘要：**
> The gain of chromosome 2p (2p) is a recurrent abnormality in chronic lymphocytic leukemia (CLL), frequently observed in advanced or relapsed disease, associated with poor prognosis and reduced response to Bruton's tyrosine kinase inhibitors (BTKi). To investigate the mechanisms of 2p-mediated resistance, we performed single-cell RNA sequencing, revealing NF-κB pathway enrichment and REL overexpression in 2p B cells. In vitro analyses confirmed increased REL expression and DNA-binding activity in a large cohort of 2p primary CLL samples. Functionally, 2p CLL cells showed reduced sensitivity to both covalent and non-covalent BTKi. Moreover, upon ibrutinib treatment, REL DNA-binding activity decreased in 2p CLL cells but remained sustained in 2p CLL cells following BCR stimulation, suggesting that persistent NF-κB activation contributes to resistance. Consistently, CRISPR/Cas9-mediated inactivation of REL in a 2p B-lymphoid cell line led to downregulation of canonical NF-κB signaling and restored BTKi sensitivity. Clinically, patients with 2p CLL treated with BTKi had a shorter time-to-next-treatment than 2p patients. Altogether, our study identifies REL overexpression as a novel 2p-driven mechanism of BTKi resistance in CLL, complementing the well described BTK and PLCG2 mutations. These findings support the clinical relevance of detecting 2p gain to guide treatment strategies and improve outcomes in CLL.

> **中文摘要：**
> 染色体 2p 臂的获得性增益是慢性淋巴细胞白血病（CLL）中一种常见的复发性异常，常见于晚期或复发性疾病，与预后不良及对布鲁顿酪氨酸激酶抑制剂（BTKi）反应降低有关。为探讨 2p 介导的耐药机制，我们进行了单细胞 RNA 测序，结果显示 2p B 细胞中 NF-κB 信号通路富集并呈现 REL 过度表达。体外分析在大量 2p 原发性 CLL 样本中证实 REL 表达上调及 DNA 结合活性增强。功能上，2p CLL 细胞对共价型与非共价型 BTKi 的敏感性均降低。此外，在伊布替尼处理后，2p CLL 细胞的 REL DNA 结合活性有所下降，但在 BCR 刺激后仍持续存在，提示持续的 NF-κB 激活可能促成耐药。相应地，通过 CRISPR/Cas9 介导在 2p B 淋巴细胞系中失活 REL 可抑制经典 NF-κB 信号并恢复对 BTKi 的敏感性。在临床上，接受 BTKi 治疗的 2p CLL 患者的下一次治疗间隔时间明显短于无 2p 增益的患者。综上所述，我们的研究确定了 REL 过度表达是 CLL 中一种由 2p 臂增益驱动的新的 BTKi 耐药机制，补充了已知的 BTK 和 PLCG2 突变机制。这些发现支持检测 2p 增益在指导治疗策略与改善 CLL 预后中的临床价值。

### 第二部分 AI 大师评价

本研究旨在揭示慢性淋巴细胞白血病中 2p 臂增益导致 BTK 抑制剂耐药的分子机制。作者通过单细胞测序及体外验证发现，REL 的过度表达及 NF-κB 通路的持续激活是核心驱动因素。进一步利用 CRISPR 技术证实，抑制 REL 可恢复药物敏感性。该研究创新性地将 2p 臂增益与 REL 介导的 NF-κB 激活联系起来，为临床检测与靶向治疗提供了新思路，但需要在更大规模的临床样本中验证其普适性。

---

## 11. 同时靶向抑制 ISG15 和 HMGCR 通过代谢崩溃破坏癌症干性并在胰腺导管腺癌中诱导合成致死性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41366470)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41366470
**DOI：** 10.1186/s13046-025-03561-x

### 第一部分 原文与翻译

**英文原标题：** The simultaneous targeted Inhibition of ISG15 and HMGCR disrupts cancer stemness through metabolic collapse and induces synthetic lethality in pancreatic ductal adenocarcinoma.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

该研究聚焦于胰腺导管腺癌，通过同时抑制 ISG15 与 HMGCR，揭示代谢崩溃与癌症干性破坏之间的联系，并诱导合成致死效应。此策略体现出针对肿瘤代谢通路的协同干预潜力，可能为难治性胰腺癌提供新的治疗思路。然而，具体机制和临床可转化性仍需进一步验证。

---

## 12. 个体化CRISPR敲入型细胞因子基因治疗用于重塑肿瘤微环境并增强实体瘤中的CAR T细胞疗法

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41366257)
**期刊：** Nature communications
**PMID：** 41366257
**DOI：** 10.1038/s41467-025-67328-w

### 第一部分 原文与翻译

**英文原标题：** Personalized CRISPR knock-in cytokine gene therapy to remodel the tumor microenvironment and enhance CAR T cell therapy in solid tumors.

> **英文摘要：**
> The immunosuppressive tumour microenvironment (TME) remains a central barrier to effective immunotherapy in solid tumours. We present a gene-therapeutic strategy that enables localized remodelling of the TME via tumour-intrinsic cytokine expression. Central to this approach is CancerPAM, a multi-omics bioinformatics pipeline that identifies and ranks patient-specific, tumour-exclusive CRISPR-Cas9 knock-in sites with high specificity and integration efficiency. Using neuroblastoma as a model, CancerPAM analysis of tumour sequencing data identifies optimal knock-in sites for pro-inflammatory cytokines (CXCL10, CXCL11, IFNG), and CancerPAM rankings correlate strongly with target-site specificity and knock-in efficiency, validating its predictive performance. CRISPR-mediated CXCL10 knock-in enhances CAR T cell infiltration and antitumour efficacy in vitro and in vivo, including humanized CD34⁺ HuNOG mice, where CXCL10-expressing tumours show stronger immune infiltration and prolonged tumour control within a reconstituted human immune microenvironment. Our findings establish a framework for safe and effective CRISPR-based cytokine delivery, integrating localized TME remodelling with cellular immunotherapies to enhance CAR T cells and other treatments in immune-refractory solid tumours.

> **中文摘要：**
> 免疫抑制性的肿瘤微环境（TME）仍然是限制实体瘤免疫治疗效果的核心障碍。我们提出了一种基因治疗策略，可通过肿瘤内源性的细胞因子表达实现TME的局部重塑。该方法的核心是CancerPAM——一个多组学生物信息学流程，用于识别和排序患者特异、肿瘤特异的CRISPR-Cas9敲入位点，具有高特异性和高整合效率。以神经母细胞瘤为模型，CancerPAM对肿瘤测序数据的分析确定了促炎性细胞因子（CXCL10、CXCL11、IFNG）的最佳敲入位点，且CancerPAM的评分与靶位点特异性和敲入效率高度相关，验证了其预测性能。CRISPR介导的CXCL10敲入在体外和体内均增强了CAR T细胞的浸润与抗肿瘤效力，包括在人源化CD34⁺ HuNOG小鼠模型中，CXCL10表达的肿瘤表现出更强的免疫浸润和更持久的肿瘤控制，体现了在重建的人类免疫微环境中的治疗潜力。我们的研究结果建立了一种安全且高效的基于CRISPR的细胞因子递送框架，将局部TME重塑与细胞免疫疗法相结合，以增强CAR T细胞及其他治疗在免疫难治性实体瘤中的疗效。

### 第二部分 AI 大师评价

本研究针对实体瘤免疫抑制性微环境提出了个体化的CRISPR基因治疗策略，利用CancerPAM多组学算法精准筛选患者专属的细胞因子敲入位点，实现肿瘤内源性细胞因子表达和微环境改造。研究在神经母细胞瘤模型中验证了CXCL10等促炎因子的敲入可显著提升CAR T细胞浸润与抗瘤效应。该工作创新性地将精准基因编辑与免疫治疗结合，展示了定制化微环境调控的潜力。局限性可能在于转化至临床时的安全性验证及异质性肿瘤中的适用性评估。

---

## 13. 结合N端蛋白质组学与机器学习探究N端精氨酰化

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41366248)
**期刊：** Nature communications
**PMID：** 41366248
**DOI：** 10.1038/s41467-025-66883-6

### 第一部分 原文与翻译

**英文原标题：** Implementing N-terminomics and machine learning to probe Nt-arginylation.

> **英文摘要：**
> N-terminal arginylation (Nt-arginylation) is a multifunctional post-translational modification (PTM) with roles in protein quality control, organelle homeostasis and stress signaling, but its study has been limited by technical challenges. Here, we develop an integrated approach combining N-terminomics with machine learning-based filtering to identify in cellulo Nt-arginylation. Using Arg-starting missed cleavage peptides as proxies for ATE1-mediated arginylation, we train a transfer learning model to predict mass spectra and retention times. By applying the prediction models with an additional statistical filter, we identify 134 Nt-arginylation sites in thapsigargin-treated HeLa cells. Arginylation is enriched in proteins from various organelles, especially at caspase cleavage and signal peptide processing sites. Eight of twelve tested proteins are further validated for their interaction with p62 ZZ domain. Temporal profiling reveals that ATF4 increases early post-stress, followed by arginylation at caspase-3 substrates and ER signal-cleaved proteins. Our approach enables sensitive detection of rare N-terminal modifications, offering potential for biomarker and drug target discovery.

> **中文摘要：**
> N端精氨酰化（Nt-arginylation）是一种具有多重功能的翻译后修饰（PTM），在蛋白质质量控制、细胞器稳态及应激信号传导中发挥作用，但由于技术限制，其研究一直受限。在本研究中，我们开发了一种整合的策略，将N端蛋白质组学与基于机器学习的筛选方法相结合，以在细胞内识别N端精氨酰化。通过使用以精氨酸起始的漏切肽段作为ATE1介导精氨酰化的替代指标，我们训练了一个迁移学习模型来预测质谱图谱和保留时间。应用预测模型并结合额外的统计滤波，我们在经他普加星（thapsigargin）处理的HeLa细胞中鉴定出134个N端精氨酰化位点。研究发现，精氨酰化在来自多种细胞器的蛋白中富集，尤其集中于半胱天冬酶切割位点及信号肽加工位点。在实验验证的12种蛋白中，有8种被进一步证实可与p62 ZZ结构域相互作用。时间动态分析显示，转录因子ATF4在应激后早期上升，随后发生于半胱天冬酶-3底物及内质网信号肽切割蛋白的精氨酰化。本研究建立的方法可灵敏检测稀有的N端修饰，为生物标志物与药物靶点的发现提供新的可能性。

### 第二部分 AI 大师评价

该研究旨在通过结合N端蛋白质组学与机器学习方法，克服检测N端精氨酰化的技术障碍。作者创新性地利用漏切肽段作为代理标志，并采用迁移学习预测质谱特征，从而在细胞水平上系统识别精氨酰化位点。结果揭示这种修饰广泛存在于细胞器蛋白中，尤其与应激及信号肽加工过程相关。该方法显著提升了稀有翻译后修饰的检测灵敏度，为理解蛋白质稳态调控及靶向药物开发提供了新思路，尽管仍需在多种生理条件下进一步验证其普适性。

---

## 14. 化学修饰的CRISPR-Cas9实现对单个G-四链体及i-构象结构的靶向，揭示配体依赖的转录扰动机制

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41366211)
**期刊：** Nature communications
**PMID：** 41366211
**DOI：** 10.1038/s41467-025-67074-z

### 第一部分 原文与翻译

**英文原标题：** Chemically modified CRISPR-Cas9 enables targeting of individual G-quadruplex and i-motif structures, revealing ligand-dependent transcriptional perturbation.

> **英文摘要：**
> The development of selective ligands to target DNA G-quadruplexes (G4s) and i-motifs (iMs) has revealed their relevance in transcriptional regulation. However, most of these ligands are unable to target individual G4s or iMs in the genome, limiting their scope. Herein, we describe an Approach to Target Exact Nucleic Acid alternative structures (ATENA) that relies on the chemical conjugation of established G4 and iM ligands to a catalytically inactive Cas9 protein (dCas9), enabling their individual targeting in living cells. ATENA demonstrates that the selective targeting of the G4 present in the oncogene c-MYC leads to the suppression of transcripts regulated exclusively by one of its promoters (P1). Conversely, targeting the c-MYC iMs on the opposite strand leads to the selective increase of P1-driven transcripts. ATENA reveals that G4-mediated transcriptional responses are highly ligand-specific, with different ligands eliciting markedly different effects at the same G4 site. We further demonstrate that the basal expression levels of the gene targeted can be used to predict the transcriptional impact associated with G4-stabilization. Our study provides a platform for investigating G4- and iM-biology with high precision, unveiling the therapeutic relevance of individual DNA structures with selectivity.

> **中文摘要：**
> 针对DNA G-四链体（G4）和i-构象（iM）的选择性配体的开发已经揭示了它们在转录调控中的重要作用。然而，大多数这类配体无法在基因组中靶向单个G4或iM，从而限制了其应用范围。在此，我们提出一种精确靶向核酸替代结构的方法（Approach to Target Exact Nucleic Acid alternative structures，ATENA），该方法依赖于将已知的G4与iM配体通过化学方式偶联至催化失活的Cas9蛋白（dCas9），从而实现其在活细胞中对单个结构的靶向。ATENA表明，选择性靶向癌基因c-MYC中存在的G4会导致仅由其一个启动子（P1）调控的转录本被抑制。相反，靶向相对链上的c-MYC iM则会选择性增加由P1驱动的转录本。ATENA揭示了基于G4的转录反应具有高度的配体特异性，不同配体在相同G4位点可引起显著不同的效应。我们进一步证明，被靶向基因的基础表达水平可用于预测与G4稳定化相关的转录影响。本研究为高精度研究G4与iM生物学提供了新平台，并揭示了特定DNA结构选择性在治疗学上的潜在意义。

### 第二部分 AI 大师评价

该研究利用化学修饰的无活性Cas9（dCas9），创新性地实现了对单个G-四链体与i-构象的精准靶向。通过ATENA平台，作者揭示了不同配体在相同G4位点引发的差异性转录效应，体现出配体依赖的调控特征。该方法不仅阐明了c-MYC启动子特异转录的结构基础，也为探索DNA替代表型的治疗靶向提供了新工具。研究具备显著的技术创新性，但未来仍需验证其在更复杂基因组环境中的普适性。

---

## 15. 与癌症相关的USP28错义突变破坏53BP1相互作用并削弱p53稳定性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41365927)
**期刊：** Nature communications
**PMID：** 41365927
**DOI：** 10.1038/s41467-025-66341-3

### 第一部分 原文与翻译

**英文原标题：** Cancer-associated USP28 missense mutations disrupt 53BP1 interaction and p53 stabilization.

> **英文摘要：**
> Cellular stress response pathways are essential for genome stability and are frequently dysregulated in cancer. Following mitotic stress, the ubiquitin-specific protease 28 (USP28) and the p53-binding protein 1 (53BP1) form a stable, heritable complex to stabilize the tumor suppressor p53, triggering cell cycle arrest or apoptosis. Here, we demonstrate that USP28 stabilizes p53 through deubiquitination. We further show that USP28 is required not only for an efficient stress response but also for maintaining basal p53 levels in some cancer cells. Loss of functional USP28 allows cells to evade mitotic stress and DNA damage responses in a manner that is specific to cell type and cancer context. We identify a prevalent, shorter USP28 isoform critical for p53 stabilization. Its C-terminal domain mediates PLK1-dependent binding to 53BP1, a dimerization-driven interaction necessary for mitotic stress memory, p53 stabilization, and cell cycle arrest. Cancer-associated missense mutations in this domain disrupt 53BP1 binding, impair nuclear localization, and destabilize USP28, compromising p53 stabilization. Notably, mutations in the 53BP1-binding domain occur more frequently in tumors than those in the catalytic domain, suggesting a potential role in cancer progression and implications for therapeutic strategies.

> **中文摘要：**
> 细胞应激反应通路对维持基因组稳定性至关重要，而在癌症中常常受到调控异常。经历有丝分裂应激后，泛素特异性蛋白酶28（USP28）与p53结合蛋白1（53BP1）形成一个稳定且可遗传的复合物，以稳定肿瘤抑制因子p53，从而触发细胞周期停滞或凋亡。在此，我们证明USP28通过去泛素化作用稳定p53。我们进一步表明，USP28不仅对有效的应激反应至关重要，也在某些癌细胞中维持基础p53水平的过程中必不可少。功能性USP28的缺失使细胞能够以依赖细胞类型和癌症背景的方式逃避有丝分裂应激与DNA损伤反应。我们鉴定出一种普遍存在的较短USP28同种型，它在p53稳定性中发挥关键作用。其C端结构域介导PLK1依赖性地与53BP1结合，这种由二聚化驱动的相互作用对于有丝分裂应激记忆、p53稳定性及细胞周期停滞都是必需的。与癌症相关的该结构域错义突变会破坏53BP1结合、损害核定位并导致USP28不稳定，从而削弱p53的稳定性。值得注意的是，53BP1结合域中的突变在肿瘤中的发生频率高于催化域中的突变，这提示其可能在癌症进展中发挥作用，并对治疗策略具有潜在意义。

### 第二部分 AI 大师评价

本文揭示USP28在应激反应及p53稳定性维持中的核心作用，系统阐明其通过去泛素化及与53BP1交互实现肿瘤抑制的机制。研究发现癌症相关的USP28错义突变破坏了与53BP1的结合与核定位，从而削弱p53稳定性，为理解癌症逃逸应激反应提供了分子基础。该工作创新性地识别了关键的USP28短同种型及PLK1依赖交互机制，同时指出突变集中于53BP1结合域可能具有肿瘤特异性意义，为靶向USP28相互作用的治疗策略提供新的思路。

---

## 16. 羊膜动物染色体与细胞核结构的进化

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41365915)
**期刊：** Nature communications
**PMID：** 41365915
**DOI：** 10.1038/s41467-025-67427-8

### 第一部分 原文与翻译

**英文原标题：** Evolution of chromosomes and nuclear architectures of amniotes.

> **英文摘要：**
> Chromosomes of mammals and reptiles have diverged extensively in sequence and three-dimensional (3D) nuclear organization since their last common amniote ancestor. The fine-scale evolutionary patterns and mechanisms underlying this divergence and the relationship between chromosome rearrangements and 3D genome architecture remain unclear. Here we reconstruct ancestral linkage groups (ALGs) of the amniote ancestor and its descendent nodes using chromosome-level assemblies from 36 species, including two newly generated genomes. We infer that most microchromosomes originated in the jawed vertebrate ancestor were retained as distinct ALGs across all ancestral amniote nodes. They were mainly involved in fusions with each other in reptiles, but underwent frequent translocations with the larger ALGs (macro-ALGs) during the mammalian evolution. Despite extensive rearrangements, sequences derived from micro-ALGs consistently occupy nuclear interior positions in both reptiles and mammals, likely enriched near nuclear speckles, supported by published lamina-positioning data and our lamin-B1 ChIP-seq data. In contrast, mammals independently evolved interchromosomal interactions associated with lineage specific transposable elements, reflecting local innovations in nuclear architecture. Together, these results reveal contrasting rearrangement regimes in mammals and reptiles, yet a conserved higher-order nuclear organization linked to ancient micro- versus macro-ALG chromatin segregation, suggesting deep constraints on chromosome evolution.

> **中文摘要：**
> 自最后一个共同的羊膜动物祖先以来，哺乳动物和爬行动物的染色体在序列和三维（3D）核结构上发生了广泛分化。驱动这种分化的精细进化模式和机制，以及染色体重排与三维基因组结构之间的关系，仍然不清楚。在此研究中，我们利用来自36个物种（包括两个新测定的基因组）的染色体水平组装，重构了羊膜动物祖先及其后代节点的祖先连锁群（ALGs）。我们推断，大多数起源于有颌脊椎动物祖先的微染色体，在所有祖先羊膜动物节点中都作为独立的ALGs被保留下来。在爬行动物中，这些微染色体主要彼此之间发生融合，而在哺乳动物进化过程中，则频繁与更大的ALGs（宏ALGs）发生易位。尽管存在广泛的重排，来源于微ALGs的序列在爬行动物和哺乳动物中都一致地位于细胞核内部区域，可能富集于核斑点附近，这一结果得到了已发表的核膜定位数据及我们自身的lamin-B1 ChIP-seq数据的支持。相比之下，哺乳动物独立演化出与谱系特异性转座元件相关的染色体间相互作用，反映出核结构的局部创新。总体而言，这些结果揭示了哺乳动物和爬行动物在染色体重排机制上的鲜明对比，但同时也展示了一种与古老的微/宏ALG染色质分隔相关的保守的高级核组织模式，提示染色体进化存在深层约束。

### 第二部分 AI 大师评价

本研究通过跨越36个物种的染色体组装，系统重建了羊膜动物祖先的染色体连锁结构，揭示了微、宏染色体在哺乳类与爬行类中不同的进化重排模式。研究发现，尽管结构发生了广泛变化，微染色体序列在核内定位模式上却表现出显著保守性，体现出核架构的深层进化约束。这种整合比较基因组学与三维核组学的数据驱动策略，为理解染色体空间组织的进化提供了新视角，其创新性显著，但受限于样本覆盖范围与转座元件功能验证的深入程度。

---

## 17. 伤害性感觉神经元衍生的NGF通过重塑成纤维性间充质基质细胞的神经源性微环境驱动肌腱病理性纤维化

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41365914)
**期刊：** Nature communications
**PMID：** 41365914
**DOI：** 10.1038/s41467-025-67396-y

### 第一部分 原文与翻译

**英文原标题：** Nociceptive sensory neuron-derived NGF orchestrates a fibrotic mesenchymal stromal cell neurogenic niche to drive tendon pathological fibrosis.

> **英文摘要：**
> Excessive fibrosis, rather than endogenous tissue regeneration, often results from peripheral tissue injury repair, presenting a significant clinical challenge due to its poor reversibility and limited treatment options. A key factor contributing to this outcome is the aberrant commitment of mesenchymal stromal cells (MSCs) to a fibrotic lineage. However, the upstream signals driving this pathological differentiation remain unclear. In this study, we identify nociceptive sensory neuron rather than local cell-derived nerve growth factor (NGF) as a critical signaling factor guiding the formation of the fibrotic MSCs neurogenic niche, thereby driving MSC-mediated fibrosis. Using nociceptive sensory denervation and NGF knockout genetic models, we demonstrate that disrupting sensory nerve innervation significantly reduces MSC-mediated fibrosis. In vitro, NGF promotes MSC fibrotic commitment through the TrkA and hypoxia-inducible factor-1α (Hif1α) signaling pathways. Therapeutically, local administration of TPX-0005 (also known as repotrectinib), a clinically used TrkA inhibitor, partially reverses excessive fibrosis and improves long-term healing outcomes. Our findings reveal a previously unrecognized neurogenic axis, highlighting the functional specificity of nociceptive sensory neuron-derived NGF in peripheral tissue repair and emphasizing the regulation of MSC neurogenic niche as a promising strategy for fibrosis prevention and treatment.

> **中文摘要：**
> 外周组织损伤修复过程中，过度的纤维化而非内源性组织再生常常发生，这由于其不可逆性和有限的治疗选择而带来了显著的临床挑战。导致这一结果的关键因素是间充质基质细胞（MSC）异常地分化为纤维化谱系。然而，驱动这种病理性分化的上游信号仍不清楚。在本研究中，我们鉴定出伤害性感觉神经元而非局部细胞源性神经生长因子（NGF），是指导纤维化MSC神经源性微环境形成的关键信号因子，从而驱动MSC介导的纤维化。通过使用伤害性感觉神经去神经化和NGF敲除的遗传模型，我们证明了破坏感觉神经支配可显著减少MSC介导的纤维化。在体外实验中，NGF通过TrkA和缺氧诱导因子-1α（Hif1α）信号通路促进MSC的纤维化分化。治疗上，局部给予临床使用的TrkA抑制剂TPX-0005（又名repotrectinib）可部分逆转过度纤维化并改善长期愈合结果。我们的研究揭示了一条此前未被认识的神经源性轴，强调了伤害性感觉神经元衍生NGF在外周组织修复中的功能特异性，并指出调控MSC神经源性微环境是预防和治疗纤维化的潜在策略。

### 第二部分 AI 大师评价

该研究揭示了伤害性感觉神经元来源的NGF在驱动MSC介导的肌腱纤维化中的关键作用，解构了神经元-基质细胞之间的病理信号网络。研究通过遗传敲除与去神经化模型验证了这一机制，并在体外实验中阐明TrkA-Hif1α通路的分子环节。进一步地，研究展示了临床药物repotrectinib对纤维化的逆转作用，具有潜在的转化医学价值。该工作创新性在于提出了外周组织修复中的神经源性微环境概念，但其临床可行性及不同组织间的普适性仍需进一步验证。

---

## 18. Geminin通过位阻阻断CDT1-MCM2相互作用而抑制DNA复制许可。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41365879)
**期刊：** Nature communications
**PMID：** 41365879
**DOI：** 10.1038/s41467-025-67073-0

### 第一部分 原文与翻译

**英文原标题：** Geminin inhibits DNA replication licensing by sterically blocking CDT1-MCM2 interactions.

> **英文摘要：**
> DNA replication is tightly regulated to occur once per cell cycle, with the MCM2-7 helicase loaded onto replication origins only during G1-phase. In higher eukaryotes, geminin negatively regulates this process during S-, G2- and M-phases by binding the essential licensing factor CDT1. Although geminin's function is crucial for genomic stability, its inhibitory mechanism remains elusive. Here, we utilise a fully reconstituted human DNA replication licensing assay to dissect geminin's role. AlphaFold modelling provides structural insights into an N-terminal CDT1-binding helix of geminin, which proves essential for inhibition. Structural docking of the CDT1-geminin complex into the ORC-CDC6-CDT1-MCM2-7 (OCCM) assembly shows that geminin's long coiled-coil domain sterically clashes with the MCM2 C-terminus, rather than directly blocking CDT1 binding to ORC-CDC6-MCM2-7. Shortening the coiled-coil preserves geminin dimerisation and CDT1 binding but abolishes inhibition, confirming its mechanistic role. Surprisingly, geminin is not able to fully inhibit DNA licensing. However, CDK1/2-cyclin A can partially inhibit DNA licensing and, in conjunction with geminin, result in a complete block. These findings uncover geminin's steric inhibitory mechanism and suggest that a dual CDK-geminin axis controls human DNA replication.

> **中文摘要：**
> DNA复制受到严格调控，以确保在每个细胞周期内仅进行一次，其中MCM2-7解旋酶仅在G1期加载到复制起点上。在高等真核生物中，geminin通过结合关键许可因子CDT1，在S期、G2期和M期负向调控这一过程。尽管geminin的功能对基因组稳定性至关重要，但其抑制机制仍不清楚。在本研究中，我们利用完全重构的人DNA复制许可检测体系解析了geminin的作用。AlphaFold建模揭示了geminin在N端的CDT1结合螺旋结构，该结构对抑制作用至关重要。将CDT1-geminin复合物结构对接到ORC-CDC6-CDT1-MCM2-7（OCCM）复合物中显示，geminin的长卷曲螺旋结构域与MCM2的C末端发生位阻冲突，而并非直接阻断CDT1与ORC-CDC6-MCM2-7的结合。缩短该卷曲螺旋可保持geminin的二聚化及其与CDT1的结合，但失去了抑制能力，从而证实了其在机制上的作用。令人意外的是，geminin无法完全抑制DNA许可。然而，CDK1/2-细胞周期蛋白A能够部分抑制DNA许可，并与geminin协同作用实现完全阻断。这些发现揭示了geminin的位阻性抑制机制，并提示CDK-geminin双重轴共同调控人类DNA复制过程。

### 第二部分 AI 大师评价

该研究旨在阐明geminin抑制DNA复制许可的分子机制。作者通过重构的人类体外DNA复制许可体系，结合AlphaFold结构预测与复合物对接分析，揭示了geminin通过其长卷曲螺旋与MCM2的位阻相互作用实现抑制，而非直接阻断CDT1与复制起始复合物结合。实验还发现，单独的geminin不足以完全抑制许可，但与CDK1/2-细胞周期蛋白A协同时可实现全面抑制。该研究在机制解释上具有创新性，为理解复制许可的多层调控提供了重要线索，但进一步验证其在细胞内动态调控中的作用仍是未来研究方向。

---

## 19. 鉴定并靶向氧化磷酸化/糖酵解以克服抗CSF-1R治疗在胶质母细胞瘤中的耐药性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41365876)
**期刊：** Cell death & disease
**PMID：** 41365876
**DOI：** 10.1038/s41419-025-08288-3

### 第一部分 原文与翻译

**英文原标题：** Identification and targeting oxidative phosphorylation/glycolysis to overcome anti-CSF-1R therapy resistance in glioblastoma.

> **英文摘要：**
> The standard care of glioblastomas (GBM) confers limited survival benefit for patients due to the rapid tumor recurrence. Targeting tumor-associated macrophages/microglia via colony-stimulating factor 1 receptor (CSF-1R) inhibition is potentially effective in suppressing GBM recurrence. However, clinical trials of CSF-1R inhibitors failed to achieve their goal due to GBM resistance to anti-CSF-1R therapy. Here, we identified and verified key resistance mechanisms of anti-CSF-1R therapy by translatome profiling-combined analyses. To solve above problem, we have established a highly stable and refractory mouse G422-GBM model, in which temozolomide (TMZ) is the most effective monotherapy but can only slightly extend animal survival. To identify effective resistance mechanism of anti-CSF1R therapy in GBM, we first apply the Translating ribosome affinity purification (TRAP) RNA-sequencing techniques in GBM tissues, which have previously used in neuroscience. TRAP-seq identified oxidative phosphorylation/glycolysis as anti-CSF1R therapy resistance mechanism, and it's combined with Cancer Therapeutics Response Portal (CTRP) identified piperlongumine (PL) or vorinostat (SAHA) as targeting drugs. PL or SAHA enhanced PLX3397 efficacy by reversing oxidative phosphorylation/glycolysis dysregulation in vitro and in vivo. The triple combination of PLX3397, TMZ, and PL/SAHA significantly improved survival in G422-GBM mice. In conclusion, targeting oxidative phosphorylation/glycolysis by PL or SAHA prominently improves therapeutic efficacy of PLX3397 + TMZ in GBM, which deserves priority for clinical trials. Our study also reveals that translatome profiling is efficient for uncovering drug-resistant targets.

> **中文摘要：**
> 由于肿瘤的快速复发，胶质母细胞瘤（GBM）的标准治疗仅能为患者带来有限的生存获益。通过抑制集落刺激因子1受体（CSF-1R）来靶向肿瘤相关巨噬细胞/小胶质细胞有望有效抑制GBM复发。然而，CSF-1R抑制剂的临床试验由于GBM对抗CSF-1R治疗的耐药性而未能达到预期目标。在本研究中，我们通过翻译组谱联合分析方法鉴定并验证了抗CSF-1R治疗的关键耐药机制。为解决上述问题，我们建立了一种高度稳定且难治的G422-GBM小鼠模型，在该模型中，替莫唑胺（TMZ）是最有效的单药治疗，但仅能略微延长动物生存期。为了鉴定GBM中抗CSF-1R治疗的有效耐药机制，我们首次在GBM组织中应用了最初用于神经科学研究的转译核糖体亲和纯化（TRAP）RNA测序技术。TRAP-seq结果显示，氧化磷酸化/糖酵解是抗CSF-1R治疗的耐药机制；结合癌症治疗反应门户（CTRP）的分析，确定了长胡椒碱（PL）和伏立诺他（SAHA）可作为针对该机制的药物。PL或SAHA能够通过逆转氧化磷酸化/糖酵解失调，在体外和体内增强PLX3397的疗效。PLX3397、TMZ与PL或SAHA的三联联合治疗显著改善了G422-GBM小鼠的生存期。总之，通过PL或SAHA靶向氧化磷酸化/糖酵解可显著提高PLX3397与TMZ联合治疗GBM的疗效，值得优先开展临床试验。本研究还揭示了翻译组谱在发现药物耐药靶点方面的高效性。

### 第二部分 AI 大师评价

本研究旨在解析抗CSF-1R治疗在胶质母细胞瘤中耐药的分子机制，并探索克服该耐药的新策略。作者利用转译组测序技术（TRAP-seq）发现氧化磷酸化/糖酵解失调是耐药的关键途径，并利用药物数据库筛选出长胡椒碱和伏立诺他作为潜在靶向药物。通过动物模型验证，联合这两种药物可显著增强PLX3397与替莫唑胺的治疗效果。研究创新性地将代谢重编程与免疫治疗耐药机制相结合，提出了可行的治疗组合方案，但临床转化仍需进一步验证。

---

## 20. 循环肿瘤DNA可优化新辅助治疗耐药性乳腺肿瘤的风险分层。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41365872)
**期刊：** Nature communications
**PMID：** 41365872
**DOI：** 10.1038/s41467-025-65432-5

### 第一部分 原文与翻译

**英文原标题：** Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors.

> **英文摘要：**
> Early-stage breast cancers resistant to neoadjuvant therapy (NAT), characterized by high residual cancer burden (RCB) after treatment, have an increased risk of metastatic recurrence. Here, we show that circulating tumor DNA (ctDNA) detected using a tumor-informed test (1) can improve risk stratification of patients with NAT-resistant tumors (RCB-II/RCB-III) and (2) predict response to NAT. Stratification using ctDNA status at pretreatment or post-NAT and ctDNA dynamics identified NAT-resistant tumors with a significantly decreased risk of metastatic recurrence. ctDNA clearance as early as week 3 across receptor subtypes predicted favorable responses to NAT, including immunotherapies. Interestingly, less than a fifth of patients with NAT-resistant tumors were ctDNA-positive post-NAT. Serial mutation profiling of NAT-resistant tumors revealed that patient-specific ctDNA assay variants remained detectable over time, including in tumors of patients ctDNA-negative post-NAT. Refining risk stratification for NAT-resistant tumors using ctDNA and understanding ctDNA shedding in these tumors could guide treatment decisions to prevent or delay metastatic recurrence.

> **中文摘要：**
> 对新辅助治疗（NAT）耐药的早期乳腺癌而言，其特点是在治疗后仍存在较高的残余肿瘤负荷（RCB），并伴随转移复发风险增加。本研究显示，通过肿瘤信息指导的检测方法检测循环肿瘤DNA（ctDNA），(1) 可改进NAT耐药肿瘤（RCB-II/RCB-III）患者的风险分层；(2) 可预测对NAT的应答情况。基于治疗前或NAT后ctDNA状态及其动态变化的分层，可识别出转移复发风险显著降低的NAT耐药肿瘤。无论受体亚型如何，早至第3周的ctDNA清除均可预测对NAT（包括免疫治疗）的良好反应。有趣的是，NAT耐药肿瘤患者中，治疗后ctDNA阳性的比例不足五分之一。对NAT耐药肿瘤进行的连续突变特征分析显示，以患者为特异的ctDNA检测变异可随时间持续检出，即使在NAT后ctDNA阴性的患者肿瘤中亦然。利用ctDNA优化NAT耐药肿瘤的风险分层，并理解这些肿瘤中ctDNA的释放特征，可能有助于制定治疗决策，以预防或延缓转移复发。

### 第二部分 AI 大师评价

本研究旨在探讨循环肿瘤DNA（ctDNA）在新辅助治疗耐药性乳腺癌患者中的风险分层与疗效预测价值。研究基于肿瘤信息指导检测，实现了对ctDNA动态变化和清除的监测，发现早期ctDNA清除可预测更好的治疗反应，而持续检测阳性与更高复发风险相关。其创新性在于结合ctDNA时序动态，将分子分层引入NAT耐药乳腺癌风险评估。尽管结果具有潜在指导意义，但仍需更大样本和长期随访来验证其临床适用性。

---

## 21. 抑制中性粒细胞胞外陷阱形成以预防术后胶质母细胞瘤复发

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41365865)
**期刊：** Nature communications
**PMID：** 41365865
**DOI：** 10.1038/s41467-025-65933-3

### 第一部分 原文与翻译

**英文原标题：** Inhibiting the formation of neutrophil extracellular traps to prevent the recurrence of post-operative glioblastoma.

> **英文摘要：**
> Glioblastoma (GBM) is a highly malignant tumor with a high postoperative recurrence rate. It is crucial to develop innovative and effective approaches to prevent its recurrence. Herein, we focus on the important roles of neutrophil extracellular traps (NETs) in the progression of GBM in mice and patients. Neutrophils accumulate around the surgical cavity and release NETs to promote the proliferation and migration of postoperative residual GBM cells. Injection of a hydrogel loaded with copper selenide nanozyme and doxorubicin into the surgical cavity successfully inhibit the formation of NETs and improve the therapeutic efficacy against GBM. 60% of treated GBM mice survive over 24 months, which are 36 times longer than those of untreated mice, and close to the lifespan of healthy mice. The treated mice preserve their essential cognitive functions and basic motor ability. This study demonstrates the great potential of modulating NETs in GBM therapy.

> **中文摘要：**
> 胶质母细胞瘤（GBM）是一种高度恶性的肿瘤，其术后复发率极高。开发创新且有效的策略以预防其复发至关重要。本研究关注中性粒细胞胞外陷阱（NETs）在小鼠和患者GBM进展中的重要作用。中性粒细胞在术腔周围聚集，并通过释放NETs促进术后残余GBM细胞的增殖与迁移。将载有硒化铜纳米酶和多柔比星的水凝胶注入术腔，可成功抑制NETs的形成，并显著提升对GBM的治疗效果。接受治疗的GBM小鼠中有60%存活超过24个月，是未治疗小鼠寿命的36倍，且接近健康小鼠的寿命。这些治疗小鼠保留了基本的认知功能和运动能力。本研究表明调控NETs在GBM治疗中的巨大潜力。

### 第二部分 AI 大师评价

该研究以抑制中性粒细胞胞外陷阱（NETs）为切入点，旨在降低术后胶质母细胞瘤的高复发风险。作者通过动物模型验证了NETs在促进残余肿瘤细胞生长与迁移中的关键作用，并利用复合材料水凝胶同时递送纳米酶和化疗药物，实现了局部NETs抑制与抗肿瘤效应的协同。实验结果显示显著延长了动物寿命并保持认知与运动功能。研究创新性地连接了免疫调控与材料治疗，但其临床安全性和可转化性仍需进一步验证。

---

## 22. 氯喹通过清除休眠癌细胞克服化疗耐药性并抑制癌症转移

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41365861)
**期刊：** Cell death & disease
**PMID：** 41365861
**DOI：** 10.1038/s41419-025-08304-6

### 第一部分 原文与翻译

**英文原标题：** Chloroquine Overcomes Chemotherapy Resistance and Suppresses Cancer Metastasis by Eradicating Dormant Cancer Cells.

> **英文摘要：**
> Cancer cell resistance and tumor relapse remain major challenges in cancer treatment. Chloroquine, an FDA-approved antimalarial drug currently undergoing clinical trials for various cancers, has emerged as a promising candidate for combination therapy with conventional anticancer agents. In this study, we demonstrate that in patients-derived osteosarcoma cells who had undergone multiple chemotherapy treatments, as well as in murine colorectal cancer cells, administration of standard chemotherapeutic agents induces autophagy, which likely serves as a cytoprotective mechanism promoting therapy resistance in at least of part of tumor population. Incorporating chloroquine into the treatment regimen effectively suppressed autophagy, significantly enhancing osteosarcoma cell death in both 2D and 3D models while simultaneously reducing cell proliferation and migration capacity. In an orthotopic in vivo model of colorectal cancer, the combination of chloroquine and oxaliplatin not only impaired tumor growth but also prevented metastatic dissemination and inhibited the formation of metastasis. Notably, comparative analyses of proliferating and dormant tumor cell populations revealed that chloroquine exerts preferential cytotoxicity toward dormant cancer cells. This suggests a dual therapeutic advantage, wherein cytostatic agents primarily eliminate proliferating cells, while chloroquine specifically eradicates dormant cancer cells, which are often implicated in tumor recurrence. Collectively, these findings highlight the potential of autophagy inhibition to enhance the chemotherapy efficacy and suggest chloroquine-based combination therapy as a promising strategy for suppressing tumor growth and metastasis, ultimately improving treatment outcomes in cancer patients.

> **中文摘要：**
> 癌细胞耐药性与肿瘤复发仍是癌症治疗中的主要挑战。氯喹是一种获得美国FDA批准的抗疟药，目前正在多种癌症的临床试验中，被认为是与常规抗癌药物联合应用的有前景候选药物。在本研究中，我们发现，在经历多次化疗的患者来源的骨肉瘤细胞以及小鼠结直肠癌细胞中，给予标准化疗药物会诱导自噬，而这种自噬可能作为一种细胞保护机制，促进至少部分肿瘤细胞群体产生治疗耐受性。将氯喹纳入治疗方案后，可有效抑制自噬，显著增强二维与三维模型中骨肉瘤细胞的死亡，同时降低细胞增殖和迁移能力。在结直肠癌的原位体内模型中，氯喹与奥沙利铂的联合不仅抑制肿瘤生长，还阻止了转移性扩散并抑制了转移灶的形成。值得注意的是，对增殖型和休眠型肿瘤细胞群的比较分析表明，氯喹对休眠癌细胞表现出优先的细胞毒性作用。这提示出一种双重治疗优势，即细胞静止剂主要清除增殖细胞，而氯喹则特异性清除常与肿瘤复发相关的休眠癌细胞。综上所述，这些发现强调了自噬抑制在增强化疗效果中的潜力，并提出氯喹联合疗法作为一种有希望的策略，用于抑制肿瘤生长和转移，从而改善癌症患者的治疗结局。

### 第二部分 AI 大师评价

该研究旨在探讨氯喹在克服化疗耐药性和抑制癌症转移中的作用机制。作者通过患者来源的骨肉瘤细胞和小鼠结直肠癌模型，验证了化疗诱导的自噬具有细胞保护性，而氯喹能有效抑制这一过程，从而增强细胞死亡并阻断转移发生。研究揭示氯喹对休眠癌细胞具有特异性毒性，提出联合化疗与自噬抑制的策略以防止肿瘤复发。该工作创新性地将“清除休眠细胞”纳入抗转移方案，但仍需进一步探索其临床安全性与长期疗效。

---

## 23. 重新定义黑色素瘤的辅助免疫治疗：一切始于免疫原化（初始激活）阶段

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41365535)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41365535
**DOI：** 10.1136/jitc-2025-013766

### 第一部分 原文与翻译

**英文原标题：** Reframing adjuvant immunotherapy in melanoma: all of it starts with priming.

> **英文摘要：**
> Checkpoint inhibitors best perform in neoadjuvant settings for a number of solid malignancies including cutaneous melanoma as compared with adjuvant schemes. A key difference between both treatment settings is the availability of tumor antigens to continuously prime antitumor T lymphocytes. Mounting evidence indicates that priming is a function chiefly performed by a subset of dendritic cells that cross-present tumor antigens rather than by malignant cells themselves. Acting in favor of these mechanisms to foster tumor-antigen priming is proposed to enhance the efficacy of adjuvant schemes.

> **中文摘要：**
> 与辅助治疗方案相比，免疫检查点抑制剂在包括皮肤黑色素瘤在内的多种实体恶性肿瘤的新辅助治疗环境中表现最佳。两种治疗环境之间的关键差异在于肿瘤抗原的可用性是否能持续促进抗肿瘤T淋巴细胞的原化（初始激活）。越来越多的证据表明，原化功能主要由一类能够交叉呈递肿瘤抗原的树突状细胞亚群承担，而非由恶性肿瘤细胞自身完成。研究者提出，促进有利于肿瘤抗原原化的机制，可能增强辅助治疗方案的疗效。

### 第二部分 AI 大师评价

该研究通过重新审视黑色素瘤辅助免疫治疗的生物学基础，强调了免疫原化阶段在治疗策略中的核心作用。摘要揭示，新辅助治疗优越的关键在于肿瘤抗原持续存在，从而维持T细胞活化。文章提出以增强树突状细胞介导的抗原交叉呈递为切入点，以改善辅助免疫治疗效果。该观点具有较强的理论创新性，为优化治疗时机与机制提供了新的思路，但仍需更多实验和临床数据验证。

---

## 24. 功能基因组学在改进过继性T细胞转移治疗中的应用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41365534)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41365534
**DOI：** 10.1136/jitc-2025-013286

### 第一部分 原文与翻译

**英文原标题：** Functional genomics for improving adoptive T-cell transfer therapies.

> **英文摘要：**
> Adoptive cell therapy (ACT) has shown remarkable success in the treatment of some malignancies, particularly leukemia. However, there are multiple factors that limit the durability of ACT in solid tumors, including dose-limiting toxicities, the immunosuppressive tumor microenvironment, and T-cell exhaustion. As the manufacture and preparation of adoptive T-cell therapies allows time and adequate conditions for ex vivo T-cell engineering, forward genetic screens can identify novel genetic targets that could improve their effectiveness. CRISPR is a commonly used functional genomics tool that has been successfully used to both enhance our understanding of mechanisms of resistance and to discover potential genetic edits to improve ACT. A complementary approach, Sleeping Beauty transposon mutagenesis provides additional opportunities to identify novel genetic edits without being constrained by the annotated human genome. Here, we summarize forward genetic screens and their tools to uncover strategies to enhance ACT. Complementary approaches can be combined and improved on to identify translatable genetic editing strategies through studies that accurately recapitulate disease-specific challenges.

> **中文摘要：**
> 过继性细胞治疗（ACT）在某些恶性肿瘤的治疗中表现出显著的成功，尤其是在白血病中。然而，在实体瘤中，ACT 的疗效持久性受到多种因素的限制，包括剂量限制性毒性、免疫抑制性肿瘤微环境以及T细胞耗竭。由于过继性T细胞治疗的制备过程提供了充足的时间与条件进行体外T细胞工程操作，正向遗传筛选可以识别出可能提高其疗效的新型遗传靶点。CRISPR是一种常用的功能基因组学工具，已被成功用于加深对抗性机制的理解，并发现能够改进ACT的潜在基因编辑靶点。互补的策略——Sleeping Beauty转座子诱变——则为识别不受注释人类基因组限制的新型基因编辑提供了更多机会。本文总结了用于揭示提升ACT策略的正向遗传筛选方法及工具。多种互补方法可结合并进一步优化，以通过准确模拟疾病特异性挑战的研究发现可转化的基因编辑策略。

### 第二部分 AI 大师评价

本研究聚焦于利用功能基因组学手段优化过继性T细胞治疗（ACT）。作者综述了CRISPR筛选和Sleeping Beauty转座子诱变等正向遗传筛选工具在识别可改善ACT疗效的基因靶点方面的应用。文章强调，这些技术能在体外工程化T细胞过程中发掘抗肿瘤效能的关键遗传调控机制，并为突破实体瘤治疗瓶颈提供思路。其创新性在于将多种基因编辑策略有机整合，用于构建更具转化潜力的ACT改进方案，但仍需在疾病特异性模型中验证可行性。

---

## 25. 迈向更优的泛肿瘤预测特征以推动精准免疫肿瘤学的发展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41365533)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41365533
**DOI：** 10.1136/jitc-2025-013213

### 第一部分 原文与翻译

**英文原标题：** Toward a better pan-tumor predictive signature for unleashing precision immuno-oncology.

> **英文摘要：**
> While immune checkpoint inhibition (ICI) has revolutionized therapy across solid tumors, resistance remains an issue. Programmed death ligand-1 immunohistochemistry has limited clinical utility, whereas tumor mutation burden and microsatellite instability are only valuable for a minority of patients and leave room for improvement. Multiomic gene signatures have enhanced prediction of immune response by incorporating interferon-gamma signaling, T-cell dysfunction and exhaustion genes, and myeloid signatures. Single-cell RNA technology has been adopted to further optimize prediction of response to immunotherapy. A novel Immune Profile Score is presented by Zander et  that builds on prior immune signatures, using DNA and RNA profiling to predict outcomes across solid tumors receiving ICIs. While this assay is promising, further prospective validation and refinements will be necessary to realize its full potential in our quest to develop precision immuno-oncology. The incorporation of readily available clinical factors (eg, sites of metastasis), host genetics, orthogonal molecular platforms (microbiome, computational pathology, spatial transcriptomics, epigenetics, proteomics, radiomics) and investigating biomarkers to predict primary refractory disease and severe toxicities may further facilitate precision medicine.

> **中文摘要：**
> 尽管免疫检查点抑制治疗（ICI）已在多种实体瘤中引发治疗革命，但耐药仍然是一个问题。程序性死亡配体1免疫组织化学检测的临床应用价值有限，而肿瘤突变负荷和微卫星不稳定性仅对少数患者具有参考意义，仍有改进空间。多组学基因特征通过整合干扰素-γ信号通路、T细胞功能障碍和衰竭相关基因以及髓系特征，从而提升了免疫反应预测能力。单细胞RNA测序技术已被采用以进一步优化免疫治疗反应的预测。Zander等人提出了一种新的免疫特征评分（Immune Profile Score），该评分基于此前的免疫特征，结合DNA和RNA分析，以预测接受ICI治疗的不同实体瘤的疗效。尽管该检测方法前景可观，但仍需进一步的前瞻性验证和完善，以充分发挥其在推进精准免疫肿瘤学方面的潜力。进一步整合易于获得的临床因素（例如转移部位）、宿主遗传特征、正交分子平台（微生物组、计算病理学、空间转录组学、表观遗传学、蛋白质组学、影像组学）以及探索用于预测原发耐药和严重毒性的生物标志物，可能进一步促进精准医学的发展。

### 第二部分 AI 大师评价

本文旨在探索优化跨肿瘤类型免疫治疗反应预测的多组学特征，提出了一种结合DNA和RNA分析的新型免疫特征评分。其创新性在于融合多组学信号与单细胞技术，试图提升预测免疫检查点抑制疗效的准确性。文章强调了模型的潜在临床应用前景，同时指出仍需前瞻性验证与模型优化。未来将整合临床、遗传与多平台分子数据，以实现真正意义上的精准免疫肿瘤学。

---

## 26. 槟榔碱上调 CD155 表达以促进口腔鳞状细胞癌的免疫逃逸。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41365532)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41365532
**DOI：** 10.1136/jitc-2025-012982

### 第一部分 原文与翻译

**英文原标题：** Arecoline upregulates CD155 expression to facilitate immune evasion in oral squamous cell carcinoma.

> **英文摘要：**
> BACKGROUND: Areca nut is the fourth most addictive substance worldwide and is a known Group 1 carcinogen. Chronic areca nut chewing has been strongly associated with the development of oral squamous cell carcinoma (OSCC), although the underlying carcinogenic mechanisms remain unclear.
> 
> METHODS: Employing spatial multiomics technology, we recently mapped the immune microenvironment of areca nut-associated OSCC and identified a marked upregulation of the immune checkpoint molecule CD155 in these tumors. Further quantitative reverse transcription-PCR, western blotting, immunofluorescence, animal experiments, etc, explored and verified the reasons for the upregulation of CD155 caused by arecoline and the results of immune escape in OSCC.
> 
> RESULTS: The investigation revealed that arecoline, a bioactive component of areca nut, induces CD155 expression in OSCC cells. Through interaction with its receptor, TIGIT, CD155 suppresses CD8 T cell function and activity, facilitating immune evasion in OSCC. Mechanistically, arecoline upregulates CD155 via activation of muscarinic acetylcholine receptors on the surface of OSCC cells, leading to RhoA-mediated inhibition of YAP phosphorylation. This promotes YAP nuclear translocation and phase separation, driving CD155 transcription. In both in vitro and in vivo models, blockade of the CD155-TIGIT signaling axis significantly enhanced the efficacy of immunotherapy in OSCC.
> 
> CONCLUSION: This study unveils a novel mechanism by which arecoline promotes immune evasion in OSCC and highlights promising immune therapeutic targets and strategies for the treatment of areca nut-associated OSCC.

> **中文摘要：**
> 背景：槟榔是全球第四大成瘾性物质，已知为国际癌症研究机构定义的Ⅰ类致癌物。长期咀嚼槟榔与口腔鳞状细胞癌（OSCC）的发生密切相关，但其潜在的致癌机制尚不清楚。
> 
> 方法：采用空间多组学技术，我们最近绘制了槟榔相关 OSCC 的免疫微环境，并发现这些肿瘤中免疫检查点分子 CD155 显著上调。进一步通过定量逆转录 PCR、西方印迹、免疫荧光、动物实验等方法，探讨并验证了槟榔碱导致 CD155 上调的原因及其在 OSCC 免疫逃逸中的作用结果。
> 
> 结果：研究发现，槟榔的生物活性成分槟榔碱可诱导 OSCC 细胞中 CD155 的表达。CD155 通过与其受体 TIGIT 相互作用，抑制 CD8 T 细胞的功能和活性，从而促进 OSCC 的免疫逃逸。在机制上，槟榔碱通过激活 OSCC 细胞表面的毒蕈碱型乙酰胆碱受体，导致 RhoA 介导的 YAP 磷酸化抑制，从而促进 YAP 的核内转位和相分离，驱动 CD155 的转录。在体内外模型中，阻断 CD155-TIGIT 信号轴可显著增强 OSCC 免疫治疗的疗效。
> 
> 结论：本研究揭示了槟榔碱促进 OSCC 免疫逃逸的新机制，并指出槟榔相关 OSCC 治疗中具有潜力的免疫治疗靶点与策略。

### 第二部分 AI 大师评价

该研究聚焦于槟榔碱在口腔鳞状细胞癌免疫逃逸中的作用机制。作者利用空间多组学结合多层次实验验证，发现槟榔碱通过毒蕈碱型乙酰胆碱受体介导 RhoA-YAP 通路激活，从而上调 CD155 表达并抑制 CD8 T 细胞功能。这一机制揭示了槟榔致癌的新免疫学维度，提示阻断 CD155-TIGIT 轴可能增强免疫治疗效果。研究创新性强，但仍需在临床层面进一步验证其转化潜力。

---

## 27. 早期三阴性乳腺癌中辅助表柔比星联合环磷酰胺序贯紫杉类化疗联合或不联合卡铂（RJBC 1501）：一项随机Ⅲ期临床试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41365333)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41365333
**DOI：** 10.1200/JCO-25-02412

### 第一部分 原文与翻译

**英文原标题：** Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial.

> **英文摘要：**
> PURPOSE: To evaluate the efficacy and safety of adjuvant epirubicin plus cyclophosphamide followed by taxanes (EC-T) versus EC-T plus carboplatin (EC-TCb) in patients with early-stage triple-negative breast cancer (TNBC).
> 
> PATIENTS AND METHODS: In this phase III trial, patients with TNBC with node-positive or node-negative (tumor size ≥1.0 cm) disease who received definitive surgery, were stratified by lymph node status and randomly assigned in a 1:1 ratio to receive four cycles of EC followed by four cycles T with or without carboplatin adjuvant chemotherapy. The primary end point was disease-free survival (DFS). Secondary end points included distant DFS (DDFS), overall survival (OS), and safety. This study had 80% power to detect a DFS hazard ratio (HR) of 0.64, with a two-sided type I error of 0.05.
> 
> RESULTS: A total of 786 patients were randomly assigned to receive EC-T (n = 391) or EC-TCb (n = 395) between March 2016 and March 2023. With a median follow-up of 4.52 (IQR, 2.83-6.06) years, 62 and 41 events were reported in the EC-T and EC-TCb arm, respectively. Adding carboplatin significantly improved DFS (HR, 0.66; [95% CI, 0.44 to 0.97];  = .034), DDFS (HR, 0.61 [95% CI, 0.38 to 0.98];  = .040), and OS (HR, 0.39 [95% CI, 0.16 to 0.94];  = .029). Grade 3 to 4 adverse events were more frequent among the EC-TCb arm (49.9%) than the EC-T arm (38.7%), primarily driven by higher incidence of neutropenia (47.0%  37.8%) and thrombocytopenia (4.5%  0%). Other grade 3 to 4 toxicities were comparable.
> 
> CONCLUSION: Adding carboplatin to adjuvant EC-T chemotherapy significantly improves DFS, DDFS, and OS in patients with early-stage TNBC. Although increased hematologic toxicity was observed, no new safety signals emerged.

> **中文摘要：**
> 目的：评估辅助化疗方案表柔比星联合环磷酰胺序贯紫杉类（EC-T）与在此基础上加用卡铂（EC-TCb）在早期三阴性乳腺癌（TNBC）患者中的疗效与安全性。
> 
> 患者与方法：在这项Ⅲ期临床试验中，入组对象为接受根治性手术后、淋巴结阳性或肿瘤直径≥1.0 cm的淋巴结阴性TNBC患者。根据淋巴结状态进行分层后，患者按1:1比例随机分配接受EC 4个周期后序贯紫杉类4个周期，是否联合卡铂的辅助化疗。主要终点为无病生存期（DFS）；次要终点包括远处无病生存期（DDFS）、总生存期（OS）及安全性。本研究设计具备80%的把握度以检测DFS风险比（HR）0.64，双侧α水平为0.05。
> 
> 结果：共786例患者在2016年3月至2023年3月间被随机分配至EC-T组（n = 391）或EC-TCb组（n = 395）。在中位随访4.52年（四分位距，2.83–6.06）时，分别在EC-T组和EC-TCb组观察到62例与41例事件。加入卡铂可显著改善DFS（HR = 0.66；95% CI，0.44–0.97；P = 0.034）、DDFS（HR = 0.61；95% CI，0.38–0.98；P = 0.040）和OS（HR = 0.39；95% CI，0.16–0.94；P = 0.029）。3–4级不良事件在EC-TCb组（49.9%）高于EC-T组（38.7%），主要由于粒细胞减少（47.0% 对 37.8%）及血小板减少（4.5% 对 0%）的发病率更高。其他3–4级毒性发生率相近。
> 
> 结论：在早期TNBC患者的辅助EC-T化疗中加入卡铂可显著改善DFS、DDFS与OS。尽管血液学毒性增加，但未发现新的安全性信号。

### 第二部分 AI 大师评价

该研究通过一项大型随机Ⅲ期试验，系统比较了EC-T化疗方案联合或不联合卡铂在早期TNBC患者中的疗效与安全性。结果显示，加入卡铂可显著改善无病生存、远处无病生存及总体生存，是一项具有临床指导意义的重要发现。研究设计严谨，随访时间充分，结论具有较高可靠性。其主要局限在于血液学毒性增加及长期生活质量尚需进一步评估。

---

## 28. 嗅觉。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41364875)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41364875
**DOI：** 10.1200/JCO-25-01650

### 第一部分 原文与翻译

**英文原标题：** Smell.

> **英文摘要：**
> A connection to a cancer patient manifested as a scent.

> **中文摘要：**
> 与一位癌症患者的联系以气味的形式呈现。

### 第二部分 AI 大师评价

这篇文章以极为简短的文字探讨了嗅觉与癌症患者之间独特的联系，可能寓意着感官体验在临床照护或共情中的象征性作用。尽管未提供具体的方法或数据，但其以极简叙述传递情感与医学人文的交融。该作品的创新性在于将嗅觉作为连接个体与疾病经历的媒介，富有启示性；然而，科学性和实证基础仍待进一步阐释与扩展。

---

## 29. 胰腺癌上皮–间质细胞可塑性的治疗性靶向

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41364739)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41364739
**DOI：** 10.1158/1078-0432.CCR-25-2052

### 第一部分 原文与翻译

**英文原标题：** Therapeutic Targeting of Epithelial Mesenchymal Cellular Plasticity in Pancreatic Cancer.

> **英文摘要：**
> PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) cells exist on a spectrum of epithelial (E) and quasimesenchymal (QM) transcriptional states with differences in sensitivity to FOLFIRINOX (FFX). GSK-3b is a key regulator PDAC cell epithelial-to-mesenchymal transition (EMT).
> 
> METHODS: In vitro analysis of PDAC cell lines combined with multi-omic analysis of data from GSK-3b inhibitor trial (NCT05077800) to evaluate treatment effects on EMT.
> 
> RESULTS: GSK-3b inhibition with elraglusib (ELRA) drives QM PDAC cells towards an E state demarcated by decreased transcription of QM genes FN1 and TGFB1 and an induction of E genes KRT8 and CEACAM6. A comparison of differentially expressed genes (DEGs) in PDAC cell lines with tumors from PDAC patients treated in a safety cohort combining FFX, ELRA and losartan (LOS) demonstrated 97 overlapping DEGs with concordant directional changes. ELRA treatment consistently suppressed EMT pathway expression. Synergy of ELRA with cytotoxic doses of FFX in 3-D culture was observed only in QM PDAC lines. The FFX/ELRA combination demonstrated initial evidence of clinical benefit with 3 of 6 patients experiencing partial response (PR) for a duration of at least 20 months. Interestingly, PRs were observed in patients with tumors demonstrating baseline high proportional QM cells that transitioned to E predominant tumors with ELRA treatment. Lastly, the influx of M1 tumor associated macrophage (TAM), CD4/CD8 lymphocytes and NK cells was observed with ELRA clinical response using a combination of GeoMx, snRNA-seq and ferumoxytol-MRI.
> 
> CONCLUSION: GSK-3b blockade synergizes with FFX by modulating PDAC plasticity while promoting the development of a tumor suppressive immune microenvironment.

> **中文摘要：**
> 研究目的：胰腺导管腺癌（PDAC）细胞存在于上皮型（E）与准间质型（QM）转录状态的连续谱上，并在对FOLFIRINOX（FFX）的敏感性方面存在差异。GSK-3β是PDAC细胞上皮–间质转化（EMT）的关键调控因子。
> 
> 研究方法：通过PDAC细胞系的体外分析，并结合GSK-3β抑制剂临床试验（NCT05077800）的多组学数据分析，以评估治疗对EMT的影响。
> 
> 研究结果：GSK-3β抑制剂elraglusib（ELRA）可驱动QM型PDAC细胞向E型状态转变，其特征为QM基因FN1和TGFB1的转录降低，以及E型基因KRT8和CEACAM6的上调。在比较PDAC细胞系与接受FFX、ELRA及氯沙坦（LOS）联合治疗的PDAC患者肿瘤的差异表达基因（DEGs）时，发现97个重叠的DEGs具有一致的表达变化方向。ELRA治疗持续抑制EMT通路基因表达。在三维培养中，仅在QM型PDAC细胞系中观察到ELRA与细胞毒性剂量FFX的协同作用。FFX/ELRA联合治疗显示了初步临床获益证据，6例患者中有3例出现部分缓解（PR），持续至少20个月。有趣的是，PR出现在那些基线时含高比例QM细胞、经ELRA治疗后转变为E型占优势肿瘤的患者中。最后，结合GeoMx、单核RNA测序（snRNA-seq）及氧化铁造影剂（ferumoxytol-MRI）的方法观察到，ELRA临床应答伴随M1型肿瘤相关巨噬细胞（TAM）、CD4/CD8淋巴细胞及NK细胞的浸润增加。
> 
> 研究结论：GSK-3β阻断通过调控PDAC可塑性与FFX产生协同效应，同时促进形成抑癌型免疫微环境。

### 第二部分 AI 大师评价

本研究旨在探索通过靶向GSK-3β抑制胰腺癌细胞上皮–间质可塑性以增强化疗疗效的机制。研究结合多组学分析与临床试验数据，发现elraglusib可诱导准间质型PDAC细胞向上皮型转变，并改善对FOLFIRINOX的反应。值得注意的是，其临床联合方案在部分患者中实现了长期部分缓解并伴随免疫微环境的重塑。该研究揭示了调控肿瘤细胞状态以增强化疗敏感性的潜在新策略，但样本量较小和机制验证仍需进一步研究。

---

## 30. 大吞饮作用和血管化决定肺鳞状细胞癌对 mTOR 抑制剂的反应。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41364715)
**期刊：** Cancer research
**PMID：** 41364715
**DOI：** 10.1158/0008-5472.CAN-25-0921

### 第一部分 原文与翻译

**英文原标题：** Macropinocytosis and Vascularization Determine Response to mTOR Inhibitors in Lung Squamous Cell Carcinoma.

> **英文摘要：**
> The capacity of cancer cells to rewire their cellular metabolism in response to therapeutic pressure confers resistance to treatments targeting key metabolic pathways, which represents a significant challenge in personalized cancer therapy for lung tumors. In this study, we investigated the mechanisms of resistance to the small molecule mTOR inhibitor TAK228 across lung squamous cell carcinoma (LUSC) models, including cell lines, xenografts, and patient-derived xenografts (PDXs). LUSC cells adapted to mTOR inhibition by engaging macropinocytosis, a form of endocytosis that facilitates enhanced uptake of extracellular nutrients, thereby increasing amino acid availability. Co-inhibition of both mTOR and macropinocytosis using small molecule inhibitors effectively reduced tumor growth. Additionally, angiogenesis limited the efficacy of inhibition of mTOR and macropinocytosis by ensuring a sufficient nutrient supply. Notably, inhibiting angiogenesis in combination with inhibitors of mTOR and macropinocytosis reduced tumor growth in xenografts and PDXs. Moreover, prolonged treatment of LUSC PDXs with TAK228 and the glutaminase inhibitor CB-839 led to upregulation of vascularization, which coincided with a rebound in tumor growth despite continued therapeutic administration. These findings highlight adaptive resistance mechanisms to small molecule inhibitors that target key metabolic pathways, lending insight into potential future clinical strategies for the treatment of LUSC.

> **中文摘要：**
> 癌细胞在治疗压力下重新塑造其细胞代谢的能力，会赋予其对靶向关键代谢通路治疗的耐药性，这对肺肿瘤的个体化治疗构成了重大挑战。在本研究中，我们探讨了肺鳞状细胞癌（LUSC）模型中对小分子 mTOR 抑制剂 TAK228 的耐药机制，这些模型包括细胞系、异种移植瘤及患者来源的异种移植瘤（PDX）。LUSC 细胞通过激活大吞饮作用（macropinocytosis）来适应 mTOR 抑制，这是一种促进胞外营养物质增强摄取的内吞作用形式，从而增加氨基酸的可利用性。使用小分子抑制剂共同抑制 mTOR 与大吞饮作用可有效降低肿瘤生长。此外，血管生成通过维持充足的营养供应限制了 mTOR 和大吞饮作用联合抑制的疗效。值得注意的是，同时抑制血管生成与 mTOR、大吞饮作用的抑制剂组合在异种移植瘤和 PDX 模型中可显著抑制肿瘤生长。进一步地，长期给予 TAK228 联合谷氨酰胺酶抑制剂 CB-839 治疗 LUSC 的 PDX 模型，可导致血管化水平上调，尽管治疗持续进行，却伴随肿瘤生长的反弹。这些发现揭示了靶向关键代谢通路的小分子抑制剂所引起的适应性耐药机制，为未来 LUSC 的临床治疗策略提供了新的启示。

### 第二部分 AI 大师评价

该研究旨在揭示肺鳞状细胞癌对 mTOR 抑制剂的耐药机制，结合细胞模型和患者来源异种移植模型，系统分析了肿瘤在代谢压力下的适应性反应。研究发现，大吞饮作用和血管化是调控对 mTOR 抑制剂反应的关键因素，并证明同时抑制这些通路可增强抗肿瘤效果。长期治疗中血管生成的代偿性上调提示了复杂的耐药网络。研究具有显著的机制创新性，为多靶点联合治疗提供了潜在策略，但仍需更多临床验证以评估转化应用价值。

---

速递结束，祝您工作愉快！